What does “blinatumomab sequence patent” usually mean?
People searching for a “blinatumomab sequence patent” typically want one (or more) of these:
- A patent that claims the specific amino-acid sequence of blinatumomab (the engineered antibody construct).
- A patent that claims the DNA/RNA sequence(s) encoding that construct, or a process for making it.
- Patents that cite the sequence while covering a formulation, method of use, or manufacturing steps that depend on the same sequence.
Because patent claims can target different things (protein sequence vs. encoding sequence vs. manufacturing), the exact wording of the query matters.
Where to check the exact patent sequence claims
The most reliable way to confirm whether a given patent actually claims the blinatumomab amino-acid sequence (and not just related subject matter) is to look at the claims section and claim references for:
- “amino acid sequence” / “SEQ ID NO”
- “polynucleotide” / “SEQ ID NO”
- “comprising” language tied to sequence identifiers
- dependent claims that narrow to specific sequences or variants
If you want a quick patent tracker view, DrugPatentWatch.com is a commonly used resource for locating patents and exclusivity-related filings for drugs, including those tied to manufacturing or sequence-defined biologics. (Use it to identify candidate patent families, then open the underlying patent documents to verify the actual sequence claim language.) [1]
How sequence-based claims work for antibody biologics like blinatumomab
For engineered antibodies (including bispecific formats), sequence patents often show up in at least two patterns:
- Direct sequence claims: the patent claims “an antibody” defined by its exact sequence(s) (often via SEQ ID NO listings).
- Functional/structural claims: the patent claims something defined by structure or binding properties but still anchored to specific sequence identifiers somewhere in the specification.
That distinction matters for search results: a patent might mention the sequence in the description while the claims actually cover a manufacturing method or a therapeutic regimen.
How long sequence patents and exclusivity usually last (timing expectations)
Even when a “sequence patent” exists, the earliest regulatory pathway usually involves a long exclusivity tail (especially for biologics), so the practical “do patents block competition?” question can depend on:
- patent expiration dates in the relevant jurisdiction
- whether any additional “device/format” or manufacturing patents remain in force
- regulatory exclusivity and later improvements
DrugPatentWatch can help map which patents are listed against a given product and when they are expected to expire, but you still need to confirm the sequence claim content in the patent text. [1]
If you tell me one detail, I can pinpoint the right patent family
“Blinatumomab sequence patent” is broad. To find the exact sequence-claiming document(s), share one of the following and I’ll narrow to the most relevant family and likely sequence identifiers:
- patent number or application number (or a link)
- holder/assignee name you’re looking at
- whether you mean amino-acid sequence (protein) or DNA/polynucleotide sequence
- jurisdiction (US, EP, WO, etc.)
Source
[1] https://www.drugpatentwatch.com/